Key Points
- Director Peter Ashley Marks bought 47,620 Alterity Therapeutics shares at $0.50 each, spending $23,810 and increasing his holdings by 33.13% to 191,340 shares.
- Alterity reported a quarterly loss of $0.28 per share on $0.31 million in revenue. The stock opened at $4.51, with a 12-month range of $2.66 to $5.89.
- Analyst sentiment is mixed but leans positive: four analysts rate the stock Buy, one Hold, and one Sell, producing a consensus “Moderate Buy” rating and a $10 average price target.
Alterity Therapeutics Limited - Sponsored ADR (NASDAQ:ATHE - Get Free Report) Director Peter Ashley Marks purchased 47,620 shares of the firm's stock in a transaction that occurred on Monday, August 31st. The stock was bought at an average price of $0.50 per share, for a total transaction of $23,810.00. Following the purchase, the director owned 191,340 shares in the company, valued at $95,670. The trade was a 33.13% increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this link.
Alterity Therapeutics Price Performance
Alterity Therapeutics stock opened at $4.51 on Wednesday. The company's 50-day moving average price is $4.78 and its two-hundred day moving average price is $4.31. Alterity Therapeutics Limited - Sponsored ADR has a twelve month low of $2.66 and a twelve month high of $5.89.
Alterity Therapeutics (NASDAQ:ATHE - Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The company reported ($0.28) earnings per share (EPS) for the quarter. The firm had revenue of $0.31 million during the quarter. On average, analysts forecast that Alterity Therapeutics Limited - Sponsored ADR will post -0.12 EPS for the current fiscal year.
Institutional Trading of Alterity Therapeutics
An institutional investor recently bought a new stake in Alterity Therapeutics stock. Citadel Advisors LLC purchased a new position in Alterity Therapeutics Limited - Sponsored ADR (NASDAQ:ATHE - Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 22,144 shares of the company's stock, valued at approximately $83,000. Citadel Advisors LLC owned 0.25% of Alterity Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 2.14% of the company's stock.
Analyst Ratings Changes
Several research analysts have weighed in on the company. LADENBURG THALM/SH SH began coverage on Alterity Therapeutics in a research report on Tuesday, June 16th. They set a "buy" rating and a $10.00 price objective on the stock. Zacks Research upgraded shares of Alterity Therapeutics to a "hold" rating in a research note on Wednesday, June 17th. UBS Group set a $12.00 price target on shares of Alterity Therapeutics in a research report on Tuesday, August 11th. JonesTrading began coverage on shares of Alterity Therapeutics in a research note on Tuesday, June 30th. They issued a "buy" rating and a $16.00 price objective for the company. Finally, Weiss Ratings reissued a "sell (e+)" rating on shares of Alterity Therapeutics in a report on Friday, July 17th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $10.00.
Read Our Latest Stock Report on ATHE
About Alterity Therapeutics
(
Get Free Report)
Alterity Therapeutics is a clinical-stage biotechnology company focused on the development of novel treatments for neurological and neurodegenerative disorders. The company's research portfolio centers on small molecules designed to target underlying disease mechanisms, with an emphasis on improving synaptic function and mitigating neuroinflammation.
Among its lead assets is trofinetide (NNZ-2566), a peptide analog derived from insulin-like growth factor 1, which is being investigated for the treatment of Rett syndrome and Fragile X syndrome in ongoing clinical trials.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
